TY - JOUR T1 - Radiomic and clinical predictors of cachexia in non-small cell lung cancer patients treated with immunotherapy JF - medRxiv DO - 10.1101/2020.10.08.20207415 SP - 2020.10.08.20207415 AU - Wei Mu AU - Evangelia Katsoulakis AU - Kenneth L. Gage AU - Chris J. Whelan AU - Matthew B. Schabath AU - Robert J. Gillies Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/11/2020.10.08.20207415.abstract N2 - Background Cachexia is present in up to 50% of patients with cancer and may contribute to primary resistance to immunotherapy. Biomarkers to predict cachexia are urgently required for early intervention. Herein, we test the hypothesis that pre-treatment 18F-FDG-PET/CT-based radiomics can be used to predict cachexia and subsequently associated with clinical outcomes among patients with advanced non-small cell lung cancer (NSCLC) who are treated with immunotherapy.Methods This retrospective multi-institution study included 210 patients with histologically confirmed stage IIIB-IV NSCLC who were treated with immune checkpoint blockade between June 2011 and August 2019. Baseline (pre-immunotherapy) PET/CT images of 175 patients from Moffitt Cancer Center were used to train (N=123) and test (N=52) a radiomics signature to predict cachexia, which was also used to predict durable clinical benefit (DCB), progression-free survival (PFS) and overall survival (OS) subsequently. An external cohort that enrolled 35 patients from James A. Haley Veterans’ Hospital (VA) was used to further validate the predictive and prognostic value of this signature.Results A radiomics signature demonstrated cachexia prediction ability with areas under receiver operating characteristics curves (AUC) of 0.77 (95%CI:0.68-0.85), 0.75 (95%CI:0.60-0.86) and of 0.73 (95%CI:0.53-0.92) in the training, test and external VA cohorts, respectively. For the further investigation of prognostic value, this signature could identify the patients with DCB with AUC of 0.67 (95%CI:0.57-0.77), 0.66 (95%CI:0.51-0.81), and 0.72 (95%CI:0.54-0.89) in these three cohorts. Additionally, the PFS and OS were significantly shorter among patients with higher radiomics signature in all the three cohorts (p<0.05).Conclusion Using PET/CT radiomics analysis, cachexia could be predicted before the start of the immunotherapy, making it possible to monitor the patients with a higher risk of cachexia and identify patients most likely to benefit from immunotherapy.Competing Interest StatementRobert J. Gillies declared a potential conflict with HealthMyne, Inc [Investor (major), Board of Advisors (uncompensated)]. Contents of this research do not represent the views of the Department of Veterans Affairs or the United States Government. The remaining authors declare no conflict of interest.Funding StatementThis study was funded by U.S. Public Health Service research grant U01 CA143062 and R01 CA190105 (awarded to Dr. Gillies). This material includes work supported with resources and the use of facilities at the James A. Haley Veterans' Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board at the University of South Florida (USF) and the James A. Haley Veterans Hospital, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe PET/CT imaging data and clinical information are not publicly available for patient privacy purposes, but are available from the corresponding authors upon reasonable request (R.J.G). ER -